About Cadila Pharmaceuticals Limited



Cadila Pharmaceuticals Limited is an Indian multinational pharmaceutical company based in Ahmedabad, Gujarat, India. Founded by Mr. Indravadan A Modi in 1951, the company manufactures and sells finished branded formulations, generic drugs and Active Pharmaceutical Ingredients (APIs) in 90 countries including USA, UK, Sweden, Japan, India, the Middle East and Russia, and has a strong foothold in Africa.


With a strong focus on innovation and research, the company’s products and services include:

  • Products spanning across:

    • 45 therapeutic categories

    • 12 specialties including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals

  • Services such as:

    • contract research

    • contract manufacturing


The company has:

  • 5 manufacturing units, comprising:

    • 3 API manufacturing units (2 in India and 1 in Ethiopia)

    • 2 formulations manufacturing units

  • 1 R&D center with 300+ scientists


Some of the product innovations – or “world firsts” – by Cadila include:

  • An Active Immunotherapyp product (Mycidac-C) for people suffering from squamous Non-Small Cell Lung Cancer (NSCLC) – providing a higher survival rate at a lower cost

  • A TB treatment drug (Risorine) that increases patient compliance

  • A pill (Polycap) that reduces the risk of CVD by 62% and stroke by 48%

  • A next generation, Virus Like Particle (VLP) based vaccine for treating seasonal and H1N1 influenza more effectively

  • Novel formulations such as:

    • Rabeloc IV: Rabeprazole sodium for intravenous administration by rapid onset of action, sustained and long term lowering of gastric pH

    • Immuvac, an immunomodulatory that enhances immunity and helps fight chemotherapy side effects better


The company has joint ventures and strategic collaborations with Apollo Hospitals (Gujarat); Helperby Therapeutics Plc, UK; Novavax Inc., USA; Pergamum AB, Sweden; and Stemcyte Inc. USA.


Cadila Pharmaceuticals Limited is a privately held company.


Cadila Pharmaceuticals Limited at-a-glance

  • Employees 7,000+
  • Markets Served 90+
  • Manufacturing Facilities 5
  • Therapeutic Categories 45+
  • Specialties 12
  • Brands 447
  • SKUs 713
  • World Firsts 6
  • Stockists 2300+
  • Patents Granted 52
  • Product Registrations (countries) 100+
  • ANDAs Filed with USFDA 10
  • USDMFs Filed 39
  • International Distributors 65+


*Source: http://cadilapharma.com/media/downloads/

Certifications cGMP compliant




TGA Australia (PIC/S)


MCC-South Africa

ISO 9001

ISO 14001










  • 1951 – Founder Indravadan A Modi decides to start a pharmaceutical business

  • 1952 – Starts production on 13th March, 1952

  • 1967 – Shifts to its own factory premises with full-fledged operations spanning production, marketing and R&D

  • 1970 – Mr. Indravadan A Modi represents the Indian Pharma industry and plays a pivotal role in shaping the Patents Act, 1970

  • 1982 – Karnavati Engineering Limited (KEL) the machinery-manufacturing arm of Cadila, commences operations

  • 1986 – Mr. Indravadan A Modi plays a key role in shaping the 1986 Drug Policy

  • 2000

    • Ties-up for research with several regional and national organizations

    • Introduces the world’s first IMMUVAC, a unique Immunomodulator

  • 2001 – Launches NEVA HIV – the world’s first whole blood Rapid HIV detection kit

  • 2002

    • Sets up Kadera Yakuhin Ltd. in Japan

    • Becomes India’s first indigenous manufacturer of natural Streptokinase – STPase

  • 2003 – Mr. Indravadan A Modi receives the Express Pharma Pulse Lifetime

Contribution Award

  • 2004

    • Launches the world’s first Parenteral Formulation of Rabeprazole (Rabeloc I.V.)

    • Submits the first IND (Investigational New Drug) with the USFDA for pulmonary tuberculosis

  • 2005

    • Operationalizes KEL’s new production line and dispatches first machinery to USA

    • Mr. Indravadan A Modi receives Lifetime Achievement Award by Gujarat Chamber of Commerce and Industry for his outstanding contribution to the industry and society

    • Publishes and presents a series of scientific papers on Immuvac, Itza and Rabeloc I.V. at UEGW (United European Gastroenterology Week, Prague), APDW (Asia Pacific Digestive Week, Beijing), AGW (Australian Gastroenterology Week), DDW (Digestive Diseases Week, Chicago, USA), ASCO (American Society of Clinical Oncology), WCOG (World Congress of Gastro)

  • 2010

    • Establishes CPL Biologicals at Dholka near Ahmedabad, Gujarat, a state-of-the-art vaccine manufacturing facility

    • Receives the prestigious Wellcome Trust Award for Affordable Healthcare in India

    • Receives financial assistance from New Millennium Indian Technology Leadership Initiative (NMITLI) to develop novel treatment for diabetes drug

  • 2011

    • Receives WHO-cGMP certification for the Ethiopia manufacturing facility, the only facility in the region

    • Receives Pre-Qualification approval from WHO, Geneva for the Dholka manufacturing facility

  • 2012

    • CPL Biologicals collaborates with the International Centre for Genetic Engineering and Biotechnology to develop novel multi-stage malaria vaccine in India based on proprietary VPL vaccine technology of Novavax

    • Completes TIPS II for cardiovascular diseases

    • CII Gujarat State Council elects Dr. Rajiv Modi as Vice Chairman

    • Initiates multinational TIPS III for treatment of Cardiovascular diseases covering 12 countries

    • Submits 10th ANDA with USFDA (the first was submitted in 2009)

    • Receives regulatory approval from MHRA, UK and TGA, Australia for Dholka manufacturing facility

  • 2013

    • CII Gujarat State Council elects Dr. Rajiv Modi as Chairman

    • Enters into a strategic collaboration with Pergamum AB, Sweden, to develop a novel treatment of infections with a unique targeting mechanism that is different from classical antibiotics

    • 6 Japan DMFs filed (till date)

    • Receives USFDA certification for Dholka formulation facility

    • Receives regulatory approval from EU GMP-Latvia for Dholka manufacturing facility

    • Files 38th USDMF (the first was filed in 2007)

    • Files 22nd API EDMF (EUDMF) for European markets

    • Signs licensing deal with UK-based Helperby Therapeutics

    • Signs joint agreement with Helperby Therapeutics, a UK-based antibiotics discovery major, on Antibiotic Drug Resistance Research & Development – to fight antibiotic resistance via patented ‘resistance breaker’ compounds

    • Launches IAMICON (Indravadan Ambalal Modi Innovation Conclave), honor Founder Chairman and celebrate innovations in Indian science

    • Launches Mycidac-C – an innovative and affordable product for patients suffering from Non-Small Cell Lung Cancer (NSCLC)



  • Founder: Mr. Indravadan A Modi

  • Chairman & Managing Director: Dr. Rajiv Indravadan Modi

  • Company Secretary: Mr. Shreyas Parikh

  • Board Members: Ms. Shilaben Indravadan Modi, Mr. Pradip N. Khandwalla, Mr. DN Khurana, Mr. Sanjay Sinha

 Cadila Pharmaceuticals Ltd. Contact Details


Cadila Pharmaceuticals Limited

Sarkhej-Dholka Road, Bhat

Ahmedabad – 382 210



Tel: +91-2718-225001

Fax: +91-2718-225039

E-mail: website@cadilapharma.co.in



CPL Inc.

1016 16th St. Nw Ste 602

Washington DC 20036-5725



Tel: 202-355 9785

Fax: 202-3559784




Cadila Pharmaceuticals (Europe) Limited

The Pavilion, Rosslyn Crescent

Harrow, Middlesex – HA1 2SZ, UK


Tel: +44 (0) 20 3583 4321

Mob: +44 (0) 74 2340 5560

E-mail: ramesh.hirpara@cadilaeurope.co.uk





Rep. Office of Cadila Pharmaceuticals Ltd.

148, Leninsky Prospekt

Flat No. 205-206



Tel: +7 495 937 5736, 937 57 36

Fax: +7 495 937 57 38





Cadila Pharmaceuticals (Sweden) AB

Gamma Building, 7th Floor

Karolinska Institutet Science Park

Tomtebodavagen 23 a

171 65, Solna



Cadila Pharmaceuticals (E.A) Ltd.

Plot No. 209 / 9721, Opp. M.P.P.S

Mombasa Road, Nairobi



Tel: +254 – 7225 09988, 7317 86006


Interpharma Industries Ltd.

(A division of Cadila Pharmaceuticals Limited)

28/30, Salvation Road, Opebi

Ikeja, Lagos



Tel: +234 81294 50990, 81294 50970



Cadila Pharmaceuticals (Ethiopia) PLC

PO Box No. 571, Code 1250

Oromia, Finfine

Misrak Shoa, Wareda: Akaki, Kebela – Gelan

Addis Ababa



Tel: +251-114-45-02-57-58


Kadera Yakuhin Limited

4-14 Kanda-Iwamotocho, Chiyoda-ku




Tel: +81-3-5295-0246

Fax: +81-3-5295-0248




* Indicates mandatory field.
Please wait while comments are being sent...